Nuvalent Inc (NUVL) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Nuvalent Inc (NUVL) has a cash flow conversion efficiency ratio of -0.083x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-70.46 Million) by net assets ($845.40 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Nuvalent Inc - Cash Flow Conversion Efficiency Trend (2019–2024)
This chart illustrates how Nuvalent Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read NUVL current and long-term liabilities for a breakdown of total debt and financial obligations.
Nuvalent Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Nuvalent Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Shenghe Resources Holding Co Ltd
SHG:600392
|
0.023x |
|
Yunnan Lincang Xinyuan Germanium Industrial Co Ltd
SHE:002428
|
-0.027x |
|
Sartorius Aktiengesellschaft
F:SRT
|
0.040x |
|
Northam Platinum Holdings Ltd
JSE:NPH
|
0.152x |
|
Noble Corporation plc
NYSE:NE
|
0.061x |
|
Beijer Ref AB (publ)
ST:BEIJ-B
|
0.028x |
|
Federal Signal Corporation
NYSE:FSS
|
0.046x |
|
Capital Securities Corp. Ltd.
SHG:601136
|
0.021x |
Annual Cash Flow Conversion Efficiency for Nuvalent Inc (2019–2024)
The table below shows the annual cash flow conversion efficiency of Nuvalent Inc from 2019 to 2024. For the full company profile with market capitalisation and key ratios, see NUVL company net worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $1.07 Billion | $-185.06 Million | -0.173x | -21.51% |
| 2023-12-31 | $700.56 Million | $-99.74 Million | -0.142x | -1.45% |
| 2022-12-31 | $462.98 Million | $-64.97 Million | -0.140x | 0.00% |
| 2021-12-31 | $285.04 Million | $-40.00 Million | -0.140x | -129.40% |
| 2020-12-31 | $-31.32 Million | $-14.95 Million | 0.477x | -14.56% |
| 2019-12-31 | $-17.26 Million | $-9.64 Million | 0.559x | -- |
About Nuvalent Inc
Nuvalent, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for patients with cancer. Its lead product candidates are NVL-520, a novel ROS1-selective inhibitor to address the clinical challenges of emergent treatment resistance, central nervous system (CNS)-related adverse events, and brain metastases that may limit the use of ROS1 tyrosine kinase inhibitor… Read more